EarlyTox Cardiotoxicity Kit Provides Biologically Relevant Cardiotoxicty Data Earlier in the Drug Discovery Process

Assessing cardiotoxicity is important during early stages of drug discovery to eliminate potentially toxic compounds from further development. This application note describes a cardiotoxicity kit that provides a robust, high throughput method, using a novel calcium sensitive dye and a proprietary masking technology, to measure the impact of pharmacological compounds on stem cell-derived cardiomyocytes.